# The Phase Ⅱ/Ⅲ Trial of LYB001

> **NCT05602558** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Yantai Patronus Biotech Co., Ltd.** · enrollment: 18000 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** LYB001
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05602558
- **Lead sponsor:** Yantai Patronus Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12
- **Primary completion:** 2023-12
- **Final completion:** 2024-02
- **Target enrollment:** 18000 (ESTIMATED)
- **Last updated:** 2022-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602558, "The Phase Ⅱ/Ⅲ Trial of LYB001". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05602558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*